| abstract |
1. A compound represented by the structure of formula (I) wherein R is COOH; and pharmaceutically acceptable salts thereof. A compound according to claim 1 in the form of a salt with a pharmaceutically acceptable acid or base. A compound according to claim 2, wherein the salt is selected from the group consisting of sodium, potassium, magnesium, hemifumarate, hydrochloride and hydrobromide salt, preferably, where the salt is a sodium salt or hemifumarate. The compound of claim 1, which is selected from the group consisting of ;; and 5. A compound according to claim 1, which is represented by the structure of formula (1) or a pharmaceutically acceptable salt thereof. A compound according to claim 5 in the form of a salt with a pharmaceutically acceptable acid or base. A compound according to claim 6, wherein the salt is selected from the group consisting of sodium, potassium, magnesium, hemifumarate, hydrochloride and hydrobromide. The compound of claim 7, wherein the salt is a sodium salt. A compound according to claim 7, wherein the salt is a hemifumarate salt. A pharmaceutical composition that contains a compound according to any one of paragraphs. 1-9 in combination with one or more pharmaceutically acceptable excipients or carriers. 11. The pharmaceutical composition of claim 10 for use in treating or preventing a condition selected from the group consisting of cardiac disorders and cardiological diseases, muscle fatigue, disorders and diseases of the musculoskeletal system, disorders and diseases of the central nervous system, cognitive dysfunction, neuromuscular disorders and diseases, disorders and diseases of the skeletal system, cancer cachexia, malignant hyperthermia, diabetes, sudden cardiac death, sudden infant death syndrome or to improve cognition active function. 12. Way to treat or prevent |